Background: Group B Streptococcus (GBS) or Streptococcus agalactiae are b-hemolytic gram-positive bacteria that colonize the lower genital tracts of women and are frequently associated with infections during pregnancy. Innate immune defenses are critical for controlling GBS dissemination and systemic infection. Mast cells are resident sentinel cells that come into contact with pathogens early during colonization and infection. Objective: We aimed to investigate the contribution of chymase to systemic GBS infection and rates of preterm birth. Methods: Pharmacologic and genetic approaches using mice deficient in mast cell protease (MCPT) 4, the mouse functional homologue of human chymase, were used. Results: Our studies show that mast cells release a protease with chymotrypsin-like cleavage specificity in response to GBS. Additionally, increased GBS systemic infection and preterm births were observed in MCPT4-deficient mice versus MCPT4-sufficient mice. Furthermore, we observed that proteolytic cleavage of the host extracellular matrix protein fibronectin by peritoneal cell-derived mast cell lysates diminished GBS adherence. Consistent with this observation, the increase in GBS dissemination and preterm births observed in MCPT4-
Group B Streptococcus (GBS) or Streptococcus agalactiae are b-hemolytic gram-positive cocci that commonly reside as commensal organisms in the lower genital tracts of adult women. However, GBS infections during pregnancy lead to preterm births, stillbirths, or infections in human neonates. In human newborns GBS infection is associated with pneumonia, bacteremia, sepsis, and meningitis, and these infections have a 10% mortality rate. 1 Morbidities caused by GBS infection include delayed development, vision and hearing loss, chronic lung disease, mental retardation, and cerebral palsy. 2 Despite the success of intrapartum antibiotic prophylaxis to prevent GBS transmission from colonized mothers to the neonate during labor and delivery, the burden of fulminant early-onset GBS sepsis caused by in utero infections remains substantial. 3, 4 Additionally, there is no effective therapy to prevent GBS-related stillbirths or preterm births. 3, 4 A better understanding of the nature of GBS virulence factors and their interactions with the host immune system is essential for therapeutic development.
Mast cells are innate immune cells that are widely distributed in tissues, especially at the interface with the external environment. Mast cells are derived from hematopoietic progenitor cells and are best known for their role in IgE-associated allergic disorders. 5 In addition to such detrimental roles, mast cells have a variety of beneficial functions because they induce immune responses that promote host resistance to certain bacterial infections. 5, 6 Recently, we reported that mast cell degranulation can contribute to host defense against systemic GBS infection. 7 However, the mechanisms by which mast cells enhance host resistance to GBS infections remain unclear.
The defining morphologic feature of mast cells is their electron-dense secretory granules, which contain large amounts of preformed mediators, such as biogenic amines, proteoglycans, and cytokines. 8 These granules also contain several mast cellspecific proteases, chymase, tryptase, and mast cell carboxypeptidase A3, release of which is induced by either IgE-dependent mast cell activation 8 or IgE-independent mechanisms. 9, 10 The overall substrate specificities of the mast cell proteases (MCPTs), in particular those of chymase, have been conserved over 200 million years of mammalian evolution. 11 This suggests the presence of a strong selective pressure for maintaining chymase specificity and an important role for MCPTs in innate immunity. Based on these notions, we here examined whether mast cell chymase provides protection against GBS infections.
Using mice deficient in MCPT4, the mouse functional homologue of human chymase, 12 we demonstrate that mast cell chymase decreases the severity of systemic GBS infection and rates of preterm birth. These can in part be attributed to the ability of chymase to downregulate GBS-extracellular matrix (ECM) interactions through proteolytic degradation of fibronectin. These results provide novel insights into mechanisms that can decrease the incidence of GBS infections in human subjects.
METHODS Ethics statement
All animal experiments were approved by the Seattle Children's Research Institutional Animal Care and Use Committee (protocols #13311 and #13907) and performed in strict accordance with the recommendations in the ''Guide for the care and use of laboratory animals'' of the National Institutes of Health (8th edition). 
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Bacterial isolates
The WT GBS strain COH1 used in this study is a clinical isolate obtained from infected human newborns. 13 The DcylE, DcovR, and DcovRDcylE mutants were previously derived from COH1. [14] [15] [16] The GBSDsfbA mutant was derived from WT GBS COH1 and was previously described. 17 Strains were grown in tryptic soy broth (Difco Laboratories, Detroit, Mich) at 308C or 378C in a 5% CO 2 atmosphere. Cell growth was monitored at 600 nm.
GBS inoculation
For GBS-induced preterm birth, we used a previously established intrauterine model of inoculation 18 rather than a vaginal model of inoculation to minimize discrepancies that can be attributed to differences in mouse vaginal persistence. 19 On day E14.5 of pregnancy, dams were inoculated with 10 7 colony-forming units (CFU) of GBS (in 100 mL) into the right horn of the uterus between the first (P1) and second (P2) fetal sacs most proximal to the cervix, as previously described. 18, 20, 21 Mice were monitored for 72 hours for signs of preterm birth (ie, vaginal bleeding with pup in birth canal or in cage). At either 72 hours or the onset of delivery (whichever occurred first), fetal survival rates were determined, and tissue was collected to assess bacterial load.
For GBS systemic infection, 9-to 12-week-old mice were intravenously injected with 5 3 10 7 CFU of either WT GBS (COH1) or isogenic GBSDsfbA. In a separate set of experiments, C57BL/6J mice were administered intraperitoneally a dose of 20 mg/kg chymostatin per mouse or vehicle control (dimethyl sulfoxide) starting 1 day before WT GBS intravenous inoculation and then every day until death for a total of 3 injections. Blood, lungs, and spleens were collected aseptically at 48 hours after infection from the inoculated mice, tissues were homogenized in sterile PBS, and GBS burden was estimated, as previously described. 7 
Other methods
See the Methods section in this article Online Repository at www. jacionline.org for the methods for flow cytometry, generation of peritoneal cell-derived mast cells (PCMCs), measurement of chymotrypsin-like activity from mast cells, assessment of mast cell bactericidal activity, production of reactive oxygen species (ROS) in neutrophils, fibronectin degradation by mast cells, and human recombinant chymase and fibronectin binding assays.
Statistical analyses
Statistical tests were performed with GraphPad Prism software (version 5.0; GraphPad Software, La Jolla, Calif). SciStatCalc was used for the Barnard test in which outcome 1 was defined as the occurrence of preterm birth and outcome 2 was the absence of it; categories 1 and 2 were 
RESULTS
Mast cells release MCPT4, a protease with chymotrypsin-like activity, on GBS exposure
It is unknown whether GBS can induce mast cells to release chymase, other proteases, or both with chymotrypsin-like activity. To test this hypothesis, PCMCs were exposed to approximately 10 6 CFU of WT GBS COH1 (belonging to capsular serotype III, an MLST-ST17 clone associated with severe neonatal infections). 13, 22, 23 Chymotrypsin-like activity in supernatants and cell lysates from GBS-stimulated mast cells was measured by using a previously described chymotryptic activity assay. 24 Our results shown in Fig 1, A, indicate that the mildly hemolytic WT GBS strain COH1 induced mast cells to release chymase. Stimulation with the Ca 21 ionophore A23187 was used as a positive control in these assays. Release of chymotrypsin-like activity was also detected when mast cells were exposed to a hyperpigmented GBS strain (DcovR), which was previously shown to induce mast cell degranulation and release of b-hexosaminidase. 7 However, even nonhemolytic GBS strains (DcylE and DcovRDcylE) induced release of chymotrypsin-like activity from mast cells (see Fig E1 in this article Online Repository at www.jacionline.org). Taken together, these data suggest that GBS induces mast cells to release a protease with chymotrypsin-like activity through a mechanism that is independent of hemolytic pigment expression.
We targeted MCPT4 because it has been shown that this protease is the major source for chymotrypsin-like activity in peritoneal cells and ear skin tissue and is the functional mouse homologue to human chymase. 12 Accordingly, chymotrypsinlike activity was not detected in supernatants and cells from PCMC-deficient MCPT4 (Mcpt4 -/-) that were exposed to GBS ) were injected in utero with 10 7 CFU of GBS WT COH1 (n 5 6 per group). Mice were monitored for signs of preterm birth up to 72 hours after inoculation. Surgery and GBS inoculation for each pregnant mouse were performed independently. Fig 1, B , Scheme of pup numbering in utero and injection site between fetuses P1 and P2 is shown. Fig 1, C 
MCPT4 decreases adverse birth outcomes associated with GBS infections
Next, we examined whether the presence or absence of MCPT4 affects the severity of GBS infections. To this end, we used Mcpt4 2/2 mice, which do not exhibit any marked defect in expression of proteases with trypsin-like or CPA activity, such as MCPT6 or mast cell carboxypeptidase A3. 12 We first examined whether MCTP4 deficiency affected GBS infection-associated preterm births by using an in utero infection model that we previously characterized. 18 In brief, mice on days 14 and 15 of pregnancy (E14.5) were inoculated in utero with approximately 10 7 CFU of WT GBS, as previously described (see Fig 1, B, for scheme of in utero inoculation). 18 The mice were then monitored for signs of preterm birth (defined as vaginal bleeding or pups in cage) for up to 72 hours after inoculation. On signs of preterm birth or at 72 hours after inoculation (whichever occurred first), the mice were euthanized, a midline laparotomy was performed, and in utero fetal death was recorded before subsequent analysis. We observed that the number of dams exhibiting preterm birth was significantly greater in Mcpt4 2/2 mice compared with Mcpt4 1/1 mice that were infected with GBS (Fig 1, C) . However, there was no significant difference in bacterial load between fetuses of GBS infected Mcpt4 1/1 and Mcpt4 2/2 mice (Fig 1,  D) . Therefore we predicted that MCPT4 confers protective effects to the pregnant dam rather than the fetuses. Consistent with this hypothesis, we found that the GBS burden was significantly increased in the spleens of pregnant mice (Fig 1, E) . Together, these data demonstrate that MCPT4 plays an important role in decreasing the incidence of GBS infection-associated preterm births.
MCPT4 decreases bacterial dissemination during systemic GBS infection
To confirm that MCPT4 contributes to decreased systemic GBS infection in adult mice, we used a previously described murine model. 7 Briefly, MCPT4-sufficient and deficient mice were intravenously injected with GBS, and bacterial burden was estimated in various tissues at 48 hours after infection (see the Methods section). As shown in Fig 2, A-C, increased GBS CFU counts were observed in the blood, spleens, and lungs of Mcpt4 2/2 mice when compared with Mcpt4
mice. Increased bacterial loads were also observed when using a pharmacologic approach in which MCPT4-sufficient mice J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 1
were treated before and during GBS systemic infection with chymostatin, a selective inhibitor of serine proteases with chymotryptic activity (see Fig E3 in this article Online Repository at www.jacionline.org). Although previous studies have suggested that chymase can mobilize inflammatory cells, 25 neutrophil numbers in the spleens of Mpct4 2/2 mice were not significantly different from those of Mcpt4 1/1 mice at 48 hours after GBS administration (Fig 2, D) . Together, these results indicate that MCPT4 deficiency increases GBS dissemination during systemic infection independently of neutrophil recruitment.
Chymase and MCPT4 are not antimicrobial to GBS
MCPTs with chymotryptic activity have been suggested to be antimicrobial to certain bacterial species. 26 Therefore we hypothesized that MCPT4 can directly kill GBS and thereby contribute to bacterial clearance. To test this hypothesis, GBS was exposed to PCMCs generated from MCPT4-sufficient and deficient mice, and bacterial survival was enumerated after 4 hours of exposure. The results shown in Fig 3, A, increasing concentrations did not lead to reduced bacterial survival (Fig 3, A) . These data indicate that chymase and MCPT4 do not have a direct bactericidal effect on GBS.
Chymase does not affect ROS generation in neutrophils
Because chymase can also influence inflammatory cell function, 25, 27, 28 we examined whether chymase influences neutrophil ROS generation. To test this, human neutrophils were pretreated with dihydrorhodamine, and oxidation to fluorescent rhodamine was monitored by using flow cytometry immediately and at 1 hour after incubation with GBS, either in the presence or absence of human chymase. As shown in Fig 3, B, production of ROS by human neutrophils on exposure to GBS was not significantly affected by the presence or absence of human chymase. These data together with in vivo observations (Fig 2, D) indicate that chymase does not influence neutrophil function and that MCPT4 does not influence neutrophil recruitment to GBS-infected organs, such as the spleen.
MCPT4 prevents systemic GBS dissemination and preterm birth by disrupting GBS interactions with the ECM
Previous studies have shown that murine 29 and rat 30 proteases with chymotryptic activity can be secreted by mast cells through an unknown mechanism that might involve piecemeal degranulation. Potentially, such released MCPTs can influence both the amount and function of mediators under homeostatic conditions. In line with this notion, fibronectin was proposed to be one of the main physiologic targets for chymase 31 and MCPT4 during baseline conditions. 12 Adherence and colonization of bacteria to host cells is a critical first step in GBS pathogenesis. A number of factors expressed on the GBS surface enable the pathogen to bind to ECM proteins, 32 including adhesion factors, such as the laminin-binding factor LmbB, 33 the fibrinogen-binding proteins FbsA and FbsB, 34, 35 and the fibronectin-binding factors BsaB 36 and SfbA. 17 GBS strains deficient in these adhesins exhibit attenuated virulence. Therefore we hypothesized that MCPT4-mediated proteolysis of fibronectin could impair the ability of GBS to bind to the ECM for subsequent dissemination. To test this hypothesis, we first assessed whether MCPT4 impairs GBS-fibronectin interactions. As shown in Fig 4, A, fulllength fibronectin was completely degraded by cell lysates generated from Mcpt4 1/1 or Mcpt4 2/2 PCMCs. However, our data show that MCPT4 is required for complete degradation of the fragments generated from full-length fibronectin. Fig 4, A and B, shows that fibronectin fragments of approximately 160 and 125 kDa are present in higher amounts in digests generated by means of fibronectin incubation with PCMC lysates from Mcpt4 2/2 mice than in digests generated by means of fibronectin incubation with PCMC lysates from Mcpt4 1/1 mice. Similar to MCPT4, human recombinant chymase also degraded full-length fibronectin and its fragments (Fig 4, C and D) .
Then we investigated whether MCPT4-mediated fibronectin cleavage generates fragments that are impaired in their ability to bind GBS. Increased GBS CFU counts were recovered from microtiter wells coated with fibronectin that has been preincubated with lysates from Mcpt4 2/2 PCMCs when compared with fibronectin that had been preincubated with lysates from Mcpt4 1/1 PCMCs (Fig 5) , indicating that MCPT4 can reduce GBS adherence to fibronectin through proteolytic cleavage of this ECM component.
We think that reduced fragmentation of fibronectin by Mcpt4
PCMCs is not a consequence of an off-target effect of the mutation in MCPT4 because similar results were obtained by adding chymostatin to Mcpt4 1/1 PCMC lysates to inhibit chymotryptic activity (see Fig E4, A and B, in this article Online Repository at www. jacionline.org). Furthermore, recombinant human chymase addition to PCMC lysates generated from MCPT4-deficient mice confers these lysates the ability to degrade fibronectin (see Fig E4, C) .
Overall, these data indicate that chymase degrades fibronectin into smaller fragments that have impaired ability to support GBS adherence.
Mcpt4 2/2 mice have been reported to exhibit higher fibronectin levels. 12 Our data suggest that GBS interactions with the ECM might be favored in these mice, leading to increased systemic infection and preterm birth. To test this hypothesis, we inoculated MCPT4-sufficient and MCPT4-deficient mice with a GBS strain deficient in expression of the fibronectin binding protein SfbA (GBSDsfbA). 17 Notably, GBSDsfbA was as effective as WT GBS in its ability to induce release of a protease with chymotrypsinlike activity from PCMCs (see Fig E5 in this article Online Repository at www.jacionline.org). As shown in Fig 6, A-C 2/2 mice can promote interactions with bacterial fibronectin-binding proteins, such as SfbA, leading to increased GBS dissemination and virulence in contrast to WT mice in which fibronectin is continuously degraded by the action of MCPT4.
We next examined GBS infection-associated preterm births in pregnant Mcpt4 2/2 mice infected with GBSDsfbA. MCPT4-deficient mice infected with GBSDsfbA did not exhibit signs of preterm births (Fig 6, D) . Moreover, CFU counts of GBSDsfbA in maternal spleens of Mcpt4 2/2 mice were similar to those in Mcpt4 1/1 mice (Fig 6, E) . Taken together, these data indicate that MCPT4-mediated proteolysis of fibronectin contributes to diminished GBS dissemination and preterm births.
DISCUSSION
Mast cells are important effector cells that participate in innate and adaptive immunity. 37 No human subject has been found who lacks mast cells. Located at strategic sites within epithelial and mucosal surfaces, mast cells perform sentinel roles in combating numerous pathogens in part through their exocytosed heparin-protease complexes. 38 By using mice with c-kit-independent mast cell deficiency, we showed recently that mast cells are required for an effective immune response during systemic GBS infections. 7 GBS are grampositive bacteria that frequently colonize the lower genital The Student t test was used for comparison between 2 groups. ***P < .005.
FIG 6. Chymase diminishes GBS infection by inhibiting GBS interactions with the ECM. A-C, Mcpt4
1/1 and Mcpt4 2/2 mice were infected intravenously with 5 3 10 7 CFU of GBS WT or GBSDsfbA. At 48 hours after infection, bacterial burden was evaluated in blood, spleens, and lungs. Data shown are from a representative experiment (of 2 independent experiments) performed with 7 animals per group. The Mann-Whitney test was used for comparisons between the 2 groups. Medians are indicated. *P < .05, **P < .01, and ***P < .005. NS, Not significant. D and E, Pregnant Mcpt4 1/1 and Mcpt4 2/2 mice were injected in utero with 10 7 CFU of GBS WT COH1 or GBSDsfbA (n 5 6 per group). Mice were monitored for signs of preterm birth up to 72 hours after inoculation. Surgery and GBS inoculation for each pregnant mouse were performed independently. Fig 6, D To address this question, we focused our attention on mast cellrestricted proteases. In mast cells these proteases can account for up to 35% of the total cellular protein, and the absolute majority of these belong to the chymotrypsin-related serine protease family. 39 The overall substrate specificity of chymase has been conserved over 200 million years of mammalian evolution. 11 This suggests the presence of a strong selective pressure for maintaining chymase specificity and an important role for this protease in innate immunity. In agreement with this hypothesis, it has been shown that MCPT4, the mouse functional homologue of chymase, 12 can protect against toxicity of certain venoms through proteolytic cleavage. However, much less is known about chymase's role in protection against bacterial pathogens. In fact, it was shown only recently that MCPT4 can reduce bacterial burden by regulated shedding of bladder epithelial cells in a murine model of urinary tract infection. 40 Considering that the female genital tract is populated by mast cells that express chymase in their granules, 41 we decided to examine the role of this protease during infection with GBS. For this purpose, we used mice deficient in MCPT4. Using an in utero infection model, we found that the number of dams exhibiting preterm birth was significantly greater in Mcpt4 2/2 mice compared with Mcpt4 1/1 mice that were infected with GBS (Fig 1, C) , with significantly higher bacterial dissemination to the maternal spleen. However, there was no significant difference in bacterial load between the fetuses of GBS-infected Mcpt4 1/1 and Mcpt4 2/2 mice (Fig 1, D) . This observation is consistent with the fact that very low chymase activity levels are observed during embryonic development (days E15-E18). 42 These findings indicate that maternal GBS systemic dissemination facilitated by MCPT4 deficiency can contribute to adverse birth outcomes. Notably, maternal sepsis caused by GBS has been associated with adverse birth outcomes in human subjects. 43 We also confirmed MCPT4's ability to decrease systemic GBS dissemination in adult mice with a systemic infection murine model.
The next question in our study was to determine how MCPT4 exerts its protective role against GBS. It has been shown that intracellular IL-15 expression in mast cells can transcriptionally limit the amount of MCPT2, resulting in decreased mast cellassociated chymotrypsin-like activity in vitro, decreased mast cell antibacterial properties, and reduced survival of mice subjected to the cecal ligation and puncture model of experimental sepsis. 26 These findings prompted us to examine the possibility that chymase has a direct killing effect against GBS. However, our in vitro data with human recombinant chymase or PCMCs that express high levels of chymotrypsin-like activity 44 do not support this hypothesis. Although these observations indicate that chymase does not participate in direct GBS killing, we cannot rule out the possibility that chymase indirectly contributes to GBS clearance by modulating the bactericidal activity of other mediators, such as eotaxins or defensins, through proteolytic cleavage. 45 Neutrophils and macrophages play critical roles in host immune defense against GBS infection.
27,28,46 Moreover, it has been shown that chymase can induce leukocyte migration and activation. 25 Despite these observations, we found no evidence that chymase can enhance myeloid cell function to clear GBS. In fact, chymase did not enhance the ability for neutrophils to produce ROS (Fig 3, B) , one of the main neutrophil mediators with GBS-killing activity. 47 Moreover, neutrophil accumulation in the spleens of GBS-infected mice was not affected by MCPT4 deficiency (Fig 2, D) .
Constitutively released chymase can have an effect on tissue homeostasis. For example, it has been shown that MCPT4 can have an effect on normal connective tissue homeostasis of the skin, 12 on baseline intestinal barrier function, 48 and on bone mass. 49 Mechanistically, these effects can be attributed to chymase's proteolytic activity when a substrate associated with disruption of homeostatic function can be identified. In vitro data with MCPT4-deficient cells have shown that fibronectin might be one of the main physiologic targets for chymase. 12 This observation is relevant to our understanding of how chymase protects against GBS dissemination because the GBS surface enables the pathogen to bind to ECM proteins partially through fibronectin-binding factors, such as BsaB 36 and SfbA. Accordingly, we demonstrated that MCPT4 degrades fibronectin to fragments with a reduced ability to bind GBS.
We were able to rescue MCPT4-deficient mice from systemic infection and high preterm birth rates when the mice were infected with a mutant strain of GBS that does not express SfbA. As far as we know, this is the first evidence revealing that MCPT4-fibronectin interactions can have an effect on host immunity against bacterial infections. However, our findings do not preclude additional mechanisms through which chymase or SfbA can influence GBS disease severity (eg, chymase-mediated proteolytic degradation of other targets and/or SfbA binding to other ECM components).
In summary, we demonstrate that MCTP4 is critical to prevent GBS infection-associated disease severity. Given that maternal sepsis can predispose infants to adverse outcomes, our studies suggest a beneficial role of chymase in decreasing maternal GBS sepsis and infant morbidity. It has been suggested that MCPTs can promote inflammation during bacterial infections through activation of proinflammatory mediators by limited proteolysis. However, several studies also indicate that MCPTs can inactivate the same proinflammatory mediators through degradation. Our findings in this study point to a different mechanism whereby mast cells release chymase to reduce host susceptibility to a systemic bacterial infection. As a consequence, a more limited inflammatory response will be required to clear the infection, thereby reducing the risks associated with hyperinflammation and sepsis in the pregnant dam, which can lead to increased risk of preterm birth. Hence our findings provide novel insight into a mechanism by which mast cells contribute to innate defense against bacterial infection. As an extension of our findings, we envision future therapeutic strategies by which the antibacterial action of chymase is exploited.
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Clinical implications: Future therapeutic strategies based on the antibacterial action of chymase might be useful to decrease GBS systemic infections and preterm birth.
METHODS
Flow cytometry
Single-cell suspensions were stained with the viability marker FVS510 (BD Biosciences) for 15 minutes on ice. Then, cells were blocked with unconjugated anti-CD16/CD32 for 10 minutes and stained with allophycocyanin-labeled anti-CD11b (2 mg/mL; clone M1/70, BD Biosciences) and phycoerythrin-labeled Ly6G antibodies (1 mg/mL; clone 1A8, BD Biosciences) for 15 minutes. Cells were fixed overnight with 1% paraformaldehyde, collected by using the LSR II instrument (BD Biosciences) with FACSDiva software, and analyzed with FlowJo software (version 8.8.7; TreeStar, Ashland, Ore).
Generation of PCMCs
Peritoneal cells from Mcpt4
1/1 and Mcpt4 2/2 mice were maintained in vitro for 3 to 8 weeks in medium containing 10 ng/mL IL-3 (Miltenyi Biotec, Auburn, Calif) and 50 ng/mL stem cell factor (Miltenyi Biotec) until the mast cells represented more than 95% of the total nonadherent cells according to May-Gr€ unwald-Giemsa staining.
Measurement of chymotrypsin-like activity from mast cells About 10 5 PCMCs were exposed to GBS WT COH1 or isogenic DsfbA, DcylE, DcovR, and DcovRDcylE, and supernatants and cells were assessed for chymotrypsin-like activity levels. Briefly, the GBS strains indicated above were grown to an OD at 600 nm (OD 600 ) of 0.3 and washed in PBS. CFU (10 6 ) were incubated with PCMCs at a multiplicity of infection (MOI) of 10 for 4 hours at 378C in DMEM plus 10% FBS. Calcium ionophore A23187 was used as a positive control and used at a concentration of 5 mmol/L (2.5 ng/ mL). Chymotrypsin-like activity was assessed by using the methods described. E1 Briefly, cells were centrifuged, and the NaCl concentration of the first supernatant (S1) was adjusted to 1 mol/L. Cell pellets were resuspended in fresh DMEM plus 10% FBS containing 1 mol/L NaCl, and the samples were centrifuged again. After removing the second supernatant (S2), the cells were resuspended again in DMEM plus 10% FBS containing 1 mol/L NaCl and 0.5% Triton X-100 to lyse the cell pellets (P). The S1, S2, and P samples were sonicated for 4 seconds by using a W-385 ultrasonic processor (Heat Systems; Ultrasonics, Farmingdale, NY) that is equipped with a microprobe. The chymotrypsin-like activity was then assessed by addition of the substrate CS-PSA (DiaPharma, West Chester, Ohio) at a final concentration of 360 mmol/L and by monitoring the change in absorbance at 405 nm. The percentage activity released was calculated by using the following formula: ðS11S2Þ=ðS11S21PÞÃ100 Assessment of mast cell bactericidal activity GBS WT (COH1) was grown to OD 0.3 and washed 2 times with PBS. Approximately 1.5 3 10 4 GBS CFU was added to 1.5 3 10 5 PCMCs (MOI 5 0.1) and incubated for 4 hours at 378C in DMEM plus 10% FBS. The same amount of bacteria was also treated with 0.1, 0.5, or 2.5 mg of the human recombinant chymase (catalog no. C8118; Sigma, St Louis, Mo). Surviving bacteria were enumerated at the end of the experiment by plating 10-fold serial dilutions on tryptic soy agar (TSA). Survival indexes were calculated as the ratio of CFU counts recovered after incubation with either PCMCs or human chymase to the CFU counts recovered in media only.
ROS production in neutrophils
Neutrophils were isolated from fresh human adult blood, as described previously. E2 Briefly, approximately 10 mL of blood was collected from independent healthy human donors in EDTA tubes (BD Biosciences). The MACSxpress Neutrophil Isolation Kit was used to isolate neutrophils, according to the manufacturer's instructions (Miltenyi Biotec). Cells were then pelleted, and red blood cells were lysed in 0.15 mol/L NH 4 Cl and 1 mmol/L NaHCO 3 . For ROS generation studies, neutrophils were washed and resuspended with HBSS at a density of 1 3 10 6 cells/mL. They were incubated with dihydrorhodamine 123 (catalog no. D1054; Sigma) at a concentration of 84 mmol/L at 378C for 20 minutes. Oxidation to fluorescent rhodamine 123 was monitored by using flow cytometry immediately and at 1 hour after incubation with bacteria (MOI 5 100) at 378C. Phorbol 12-myristate 13-acetate was used at a concentration of 20 nmol/L, and 0.5 mg of human chymase was used for the corresponding treatments.
Fibronectin degradation by mast cells and human recombinant chymase
Given its high degree of homology between mouse and human fibronectin, the latter was used for in vitro studies. BLAST Intensity of a band that corresponds to fibronectin fragment=Intensity of full À length fibronectinð220 kDaÞÃ100
Fibronectin-binding assays
The effect of mouse MCPT4 on GBS-fibronectin interactions was assessed by using a modified version of a previously described protocol. E3 Briefly, a 96-well plate was coated overnight at 48C with either intact fibronectin or fibronectin fragments (obtained by incubation of 5 mg of fibronectin with the PCMC lysate preparations described above). WT GBS COH1 was grown to an OD of 0.3 and washed 2 times with PBS. The fibronectin-coated plates were washed 3 times with PBS, and approximately 10 5 CFU of GBS WT COH1 were added for 30 minutes at 378C. The plates were then washed 3 times, and the adherent bacteria were recovered by means of trypsinization for 10 minutes at 378C. Bacteria were enumerated by using 10-fold serial dilutions and plating. ) starting 1 day before intravenous WT GBS inoculation and then every day until death for a total of 3 injections. Mice were intravenously infected with 5 3 10 7 CFU of WT GBS COH1. At 48 hours after infection, bacterial burden was evaluated in blood, spleens, and lungs. Data represent 2 independent experiments performed with 8 animals per group. The MannWhitney test was used for comparisons between the 2 groups. Medians are indicated. *P < .05 and ***P < .005. PCMCs were treated with 10 6 CFU of WT GBS COH1 or an isogenic DsfbA mutant at an MOI of 10 for 4 hours. Calcium ionophore A23187 (5 mmol/L) was included as a positive control. Percentage of chymotrypsin-like activity release was assessed by measuring chymotrypsin-like activity in the mast cell supernatants and cell lysates. Data shown were obtained from 3 independent experiments (n 5 3). **P < .01 and ***P < .001 versus unstimulated cells (Student t test; error bars indicate 1 SEM).
